180 Life Sciences Market cap
What is the Market cap of 180 Life Sciences?
The Market cap of 180 Life Sciences Corp. is $11.75M
What is the definition of Market cap?
Market capitalization is the market value at a point in time of the shares outstanding of a publicly traded company, being equal to the share price at that point of time times the number of shares outstanding.
= outstanding shares * previous day’s close
As outstanding stock is bought and sold in public markets, capitalization could be used as an indicator of public opinion of a company's net worth and is a determining factor in some forms of stock valuation.
Market capitalization is used by the investment community in ranking the size of companies, as opposed to sales or total asset figures. It is also used in ranking the relative size of stock exchanges, being a measure of the sum of the market capitalizations of all companies listed on each stock exchange. In performing such rankings, the market capitalizations are calculated at some significant date, such as 30 June or 31 December.
The total capitalization of stock markets or economic regions may be compared with other economic indicators. The total market capitalization of all publicly traded companies in the world was US$51.2 trillion in January 2007 and rose as high as US$57.5 trillion in May 2008 before dropping below US$50 trillion in August 2008 and slightly above US$40 trillion in September 2008. In 2014 and 2015, global market capitalization was US$68 trillion and US$67 trillion, respectively.
Market cap of companies in the Health Care sector on NASDAQ compared to 180 Life Sciences
What does 180 Life Sciences do?
180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Companies with market cap similar to 180 Life Sciences
- Sandmartin International has Market cap of $11.72M
- NanoVibronix Inc has Market cap of $11.73M
- Frankly has Market cap of $11.73M
- Growners SA has Market cap of $11.73M
- LFG Investment has Market cap of $11.74M
- Global Net Lease has Market cap of $11.74M
- 180 Life Sciences has Market cap of $11.75M
- Chembio Diagnostics has Market cap of $11.75M
- Lykis has Market cap of $11.75M
- Steel City Securities has Market cap of $11.75M
- Blue Star Foods has Market cap of $11.76M
- UMT United Mobility Technology AG has Market cap of $11.76M
- Coffee Co Inc has Market cap of $11.76M